Cordarone, Desethylamiodarone, Pacerone
Monitoring Amiodarone therapy, especially when amiodarone is coadministered with other drugs that may interact
Evaluation of possible amiodarone toxicity
Assessment of patient compliance
Numerous drug interactions have been observed for amiodarone. Clinical follow-up is essential for optimal use of amiodarone. Therapeutic drug monitoring for amiodarone and coadministered medications is highly recommended.
Specimens that are obtained from gel tubes or anticoagulate collections can cause assay interference.
Therapeutic concentration: 0.5-2.0 mcg/mL
Toxic concentration: >2.5 mcg/mL
No therapeutic range established for desethylamiodarone; activity and serum concentration are similar to parent drug.
Clinical effects generally require serum concentrations above 0.5 mcg/mL.
Increased risk of toxicity is associated with amiodarone concentrations above 2.5 mcg/mL.
Although therapeutic and toxic ranges are based only on the parent drug, the active metabolite N-desethylamiodarone should be present in similar concentrations to amiodarone.